Vantage Biosciences is targeting the root cause of vision loss resulting from diabetes – the neuroinflammatory insult that precedes microangiopathy and leads to degeneration of the neurovascular unit of the eye.
Vantage Biosciences utilises cutting-edge science to address inflammatory conditions influenced by leukocyte trafficking and oxidative stress.
Enabling patient access to disease modifying therapy for diabetic eye disease by developing drugs that intervene at the earliest point of disease biology.
Vantage Biosciences is a UK based clinical stage biotechnology company, with a potential for developing the first oral treatment for diabetic retinopathy.
The Vantage Biosciences team have a breadth of expertise in clinical trial execution, and are rapidly advancing the lead programme into a Phase 2 clinical trial.
With insights from the world-leading advisory board, we are progressing our highly selective AOC-3 inhibitor in non-proliferative diabetic retinopathy.